Isabel Vilaseca1,2,3,4, Ximena Terra3,5, Francesc Xavier Avilés-Jurado6,7,8,9, Carmen Muñoz10, Carla Meler11,12, Joan Carles Flores13, Josep Gumà14, Ester Benaiges15,16, Josefina Mora17, Mercedes Camacho18, Xavier León19. 1. Otorhinolaryngology Head-Neck Surgery Department, Hospital Clínic, IDIBAPS Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain. 2. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, 2017-SGR-01581, Barcelona, Spain. 3. Asociación Española Contra el Cáncer (AECC), Madrid, Spain. 4. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-Res), Madrid, Spain. 5. MoBioFood Research Group, Biochemistry and Biotechnology Department, Universitat Rovira i Virgili, Tarragona, Spain. 6. Otorhinolaryngology Head-Neck Surgery Department, Hospital Clínic, IDIBAPS Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain. faviles@clinic.cat. 7. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, 2017-SGR-01581, Barcelona, Spain. faviles@clinic.cat. 8. Asociación Española Contra el Cáncer (AECC), Madrid, Spain. faviles@clinic.cat. 9. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Madrid, Spain. faviles@clinic.cat. 10. Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain. 11. Doctoral Programme in Biomedicine, Universitat Rovira i Virgili, Tarragona, Spain. carlaameler@gmail.com. 12. Otorhinolaryngology Department, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain. carlaameler@gmail.com. 13. Otorhinolaryngology Department, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain. 14. Oncology Department, Intsitut d'Investigació Sanitària Pere Virgili, Hospital Universitari Sant Joan de Reus, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain. 15. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Madrid, Spain. 16. Endocrinology and Nutrition Department, Hospital Universitari de Tarragona Joan XXIII, Insitut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain. 17. Biochemistry Department, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 18. Genomics of Complex Diseases, Research Institute Hospital Sant Pau, IIB Sant Pau, Barcelona, Spain. 19. Otorhinolaryngology Head-Neck Surgery Department, Hospital de la Santa Creu i Sant Pau and Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN, MICINN, ISCIII), Universitat Autònoma de Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: The identification of prognostic non-invasive biomarkers is a priority for cancer patients' care. Circulating microRNA (miRNAs) have been described in numerous human malignancies as diagnostic, prognostic, and therapeutic cancer biomarkers. The aim of our study was to analyze the expression profile of a set of miRNAs, involved in the modulation of the glycolytic pathway, as prognostic factors in human head and neck squamous cell carcinomas (HNSCC). METHODS: Serum samples of 54 patients with untreated HNSCC were obtained at the time of diagnosis. The prognostic value of circulating miR-26b, miR-124, miR-155 and miR-375 was evaluated towards disease-free survival. RESULTS: We found that there were optimal miRNAs cut-off values for lower risk of recurrence in HNSCC patients. Kaplan-Meier curves showed that higher levels of miR-26b and lower levels of miR-155 were associated with better disease-free survival rates. In the multivariate analysis, patients with serum miR-26b > 0.062 and miR-155 < 0.159 presented more than 2.9 times lower risk of poor outcome. CONCLUSION: Our results suggest that two miRNAs that modulate the glycolytic pathway, miR-26b and miR-155, are independently associated with the risk of recurrence in patients with HNSCC. The overall results in this study supports the evidence that the glucose homeostasis may be a target to improve the outcomes for patients with HNSCC. LEVEL OF EVIDENCE: Individual retrospective cohort study (2b).
BACKGROUND: The identification of prognostic non-invasive biomarkers is a priority for cancerpatients' care. Circulating microRNA (miRNAs) have been described in numerous humanmalignancies as diagnostic, prognostic, and therapeutic cancer biomarkers. The aim of our study was to analyze the expression profile of a set of miRNAs, involved in the modulation of the glycolytic pathway, as prognostic factors in human head and neck squamous cell carcinomas (HNSCC). METHODS: Serum samples of 54 patients with untreated HNSCC were obtained at the time of diagnosis. The prognostic value of circulating miR-26b, miR-124, miR-155 and miR-375 was evaluated towards disease-free survival. RESULTS: We found that there were optimal miRNAs cut-off values for lower risk of recurrence in HNSCC patients. Kaplan-Meier curves showed that higher levels of miR-26b and lower levels of miR-155 were associated with better disease-free survival rates. In the multivariate analysis, patients with serum miR-26b > 0.062 and miR-155 < 0.159 presented more than 2.9 times lower risk of poor outcome. CONCLUSION: Our results suggest that two miRNAs that modulate the glycolytic pathway, miR-26b and miR-155, are independently associated with the risk of recurrence in patients with HNSCC. The overall results in this study supports the evidence that the glucose homeostasis may be a target to improve the outcomes for patients with HNSCC. LEVEL OF EVIDENCE: Individual retrospective cohort study (2b).
Entities:
Keywords:
Glycolysis; Head and neck cancer; Non-invasive biomarker; Prognosis; miRNAs
Authors: F Chiesa; N Tradati; S Mauri; L Calabrese; R Grigolato; G Giugliano; S Zurrida; E Chiesa; M Squadrelli; G Viale; E Maiorano Journal: Anticancer Res Date: 1998 Nov-Dec Impact factor: 2.480
Authors: Manchao Zhang; Longzhu Piao; Jharna Datta; James C Lang; Xiujie Xie; Theodoros N Teknos; Anna K Mapp; Quintin Pan Journal: Mol Cancer Ther Date: 2015-07-30 Impact factor: 6.261
Authors: Alvaro D Ortega; María Sánchez-Aragó; Daniel Giner-Sánchez; Laura Sánchez-Cenizo; Imke Willers; José M Cuezva Journal: Cancer Lett Date: 2008-09-14 Impact factor: 8.679
Authors: Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis Journal: Int J Mol Sci Date: 2022-07-26 Impact factor: 6.208